Sangamo Therapeutics (NASDAQ: SGMO) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Sangamo Therapeutics to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, dividends, profitability, risk and valuation.
Insider & Institutional Ownership
64.4% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.5% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Sangamo Therapeutics has a beta of 3.15, suggesting that its share price is 215% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics’ peers have a beta of 5.94, suggesting that their average share price is 494% more volatile than the S&P 500.
This is a breakdown of current ratings for Sangamo Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sangamo Therapeutics Competitors||859||3211||11651||231||2.71|
Sangamo Therapeutics currently has a consensus target price of $18.60, suggesting a potential upside of 17.35%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.77%. Given Sangamo Therapeutics’ peers higher possible upside, analysts plainly believe Sangamo Therapeutics has less favorable growth aspects than its peers.
This table compares Sangamo Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sangamo Therapeutics Competitors||-5,311.45%||-218.34%||-39.53%|
Valuation & Earnings
This table compares Sangamo Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sangamo Therapeutics||$19.39 million||-$71.65 million||-22.97|
|Sangamo Therapeutics Competitors||$284.28 million||$33.78 million||83.08|
Sangamo Therapeutics’ peers have higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company’s product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.